CTLA4 and cancer: There is evidence of gastrointestinal side effects in cancer patients treated with anti-CTLA-4 antibody, associated with an increased expression of the biliary glycoprotein CECAM-1 and the cell surface glycoprotein CD177, which is directly correlated with neutrophil activation (Friedlander et al., 2018).